Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 1
2018 3
2021 2
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.
de Vogel S, Seeger JD, Arana A, Margulis AV, McQuay LJ, Perez-Gutthann S, Hallas J, Kristiansen NS, Linder M, Odsbu I, Suehs B, Xu Y, Uribe C, Appenteng K, Robinson NJ. de Vogel S, et al. Among authors: kristiansen ns. Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5799. doi: 10.1002/pds.5799. Pharmacoepidemiol Drug Saf. 2024. PMID: 38680102 Review.
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. Phiri K, et al. Among authors: kristiansen ns. Curr Med Res Opin. 2021 May;37(5):867-877. doi: 10.1080/03007995.2021.1891035. Epub 2021 Mar 8. Curr Med Res Opin. 2021. PMID: 33591859
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigí-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Hallas J, Pottegård A, Rebordosa C. Rivero-Ferrer E, et al. Among authors: kristiansen ns. Clin Drug Investig. 2022 Apr;42(4):319-331. doi: 10.1007/s40261-022-01120-2. Epub 2022 Mar 15. Clin Drug Investig. 2022. PMID: 35290649 Free PMC article.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Among authors: kristiansen ns. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV, Linder M, Arana A, Pottegård A, Berglind IA, Bui CL, Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S, Hallas J. Margulis AV, et al. Among authors: kristiansen ns. PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456. eCollection 2018. PLoS One. 2018. PMID: 30260993 Free PMC article.
Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.
Hallas J, Margulis AV, Pottegård A, Kristiansen NS, Atsma WJ, Appenteng K, de Vogel S, Kaye JA, Perez-Gutthann S, Arana A. Hallas J, et al. Among authors: kristiansen ns. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):612-619. doi: 10.1111/bcpt.12965. Epub 2018 Feb 22. Basic Clin Pharmacol Toxicol. 2018. PMID: 29345103 Free article.